Weica: The UK approves intravenous infusion of luncani antibodies to maintain dosage for early Alzheimer's disease treatment.

Wei Cai and Bo Jian announced that the humanized monoclonal antibody Lunquinimab has been approved by the UK Medicines and Healthcare products Regulatory Agency for intravenous maintenance dosing every four weeks. In August 2024, Lunquinimab was approved in the UK for the treatment of AD-related mild cognitive impairment and mild AD patients, suitable for adult patients who are carriers of the Apolipoprotein E 4 heterozygous or non-carriers. With the approval of this intravenous maintenance dosing regimen, patients can switch to a 10 mg/kg maintenance dose every four weeks after 18 months of treatment with a 10 mg/kg dose every two weeks, or continue with the 10 mg/kg dose every two weeks.